Guardant Health Inc. (GH)
Guardant Health (GH) Moves 6.9% Higher: Will This Strength Last?
Guardant Health (GH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Guardant Health Gets FDA Nod on Colorectal Cancer Blood Test
Guardant Health (GH) on Monday said that its Shield colorectal cancer-screening blood test has received approval from the U.S. Food and Drug Administration (FDA), sending shares higher.
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
On Monday, the FDA approved Guardant Health Inc.'s GH Shield blood test for colorectal cancer (CRC) screening in adults age 45 and older who are at average risk for the disease.
Guardant Health Shares Rise 7% After FDA Approves Its Blood Test For Colon Cancers
Shares of Guardant Health jumped 7% on Monday, after the Food and Drug Administration approved the company's blood test to screen for colon cancer, a new testing method the company said is intended to boost the rate of screenings for the disease as fewer eligible Americans opt for colonoscopies.
US FDA approves Guardant Health's blood-based cancer test
The U.S. Food and Drug Administration on Monday approved Guardant Health's blood test to detect a cancer that starts in the colon or rectum.
Guardant Health (GH) Just Overtook the 20-Day Moving Average
After reaching an important support level, Guardant Health (GH) could be a good stock pick from a technical perspective. GH surpassed resistance at the 20-day moving average, suggesting a short-term bullish trend.
Guardant Health (GH) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, Guardant Health, Inc. (GH) could be a good stock pick from a technical perspective. GH recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Guardant Health (GH) Recently Broke Out Above the 200-Day Moving Average
From a technical perspective, Guardant Health (GH) is looking like an interesting pick, as it just reached a key level of support. GH recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Guardant Health Rockets After FDA Panel Recommends Approval For Blood-Based Colon Cancer Test
Guardant Health stock rocketed Friday after an FDA panel recommended the agency approval Guardant's blood-based colon cancer screening test.
U.S. FDA advisers back approval for Guardant's blood-based cancer test
Advisers to the U.S. Food and Drug Administration on Thursday recommended for the approval of Guardant Health's blood test to detect a cancer that begins in the colon or rectum.
Amalgamated Bank Sells 981 Shares of Guardant Health, Inc. (NASDAQ:GH)
Amalgamated Bank cut its stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 5.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,077 shares of the company’s stock after selling 981 shares during the period. Amalgamated Bank’s holdings in Guardant Health were worth $435,000 as of its most recent SEC filing. Several other large investors have also bought and sold shares of the stock. Headlands Technologies LLC grew its position in shares of Guardant Health by 362.3% during the 4th quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock valued at $64,000 after acquiring an additional 1,844 shares during the period. Van ECK Associates Corp lifted its stake in Guardant Health by 29.4% in the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock valued at $73,000 after purchasing an additional 614 shares during the last quarter. Nisa Investment Advisors LLC grew its holdings in Guardant Health by 26.1% during the third quarter. Nisa Investment Advisors LLC now owns 3,450 shares of the company’s stock valued at $102,000 after purchasing an additional 713 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in Guardant Health in the third quarter worth $115,000. Finally, AXQ Capital LP bought a new stake in shares of Guardant Health in the third quarter valued at $202,000. 92.60% of the stock is currently owned by institutional investors. Analyst Upgrades and Downgrades Several research firms have recently weighed in on GH. JPMorgan Chase & Co. cut their price target on Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research note on Friday, February 23rd. The Goldman Sachs Group reduced their target price on shares of Guardant Health from $32.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, April 15th. Guggenheim restated a “neutral” rating on shares of Guardant Health in a research note on Friday, April 5th. Canaccord Genuity Group cut their price objective on shares of Guardant Health from $45.00 to $30.00 and set a “buy” rating for the company in a report on Monday, April 29th. Finally, Piper Sandler lowered their target price on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, February 26th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $35.78. View Our Latest Report on GH Guardant Health Trading Down 3.4 % Shares of GH stock opened at $25.36 on Monday. The company has a market capitalization of $3.10 billion, a PE ratio of -6.47 and a beta of 0.92. Guardant Health, Inc. has a 52-week low of $15.81 and a 52-week high of $41.06. The business’s fifty day moving average is $19.03 and its 200 day moving average is $22.27. The company has a debt-to-equity ratio of 16.70, a quick ratio of 5.66 and a current ratio of 5.95. Guardant Health (NASDAQ:GH – Get Free Report) last released its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share for the quarter, missing the consensus estimate of ($0.93) by ($0.65). The business had revenue of $155.05 million during the quarter, compared to analysts’ expectations of $151.71 million. Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. On average, equities research analysts anticipate that Guardant Health, Inc. will post -3.49 EPS for the current fiscal year. Insider Buying and Selling at Guardant Health In related news, insider Kumud Kalia purchased 2,187 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were purchased at an average price of $17.82 per share, with a total value of $38,972.34. Following the acquisition, the insider now directly owns 12,722 shares of the company’s stock, valued at $226,706.04. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.20% of the stock is currently owned by company insiders. Guardant Health Company Profile (Free Report) Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
